Evidence map›Paper›PMID 38868548›Full record

ArticleCureus2024

Ferrer Adjustable Speaking Valve for Early Phonation in a Deconditioned Patient.

Rafael Cartaya, Syed A A Rizvi, Viviane Manara, Mari L Tesch, Rahaghi Franck

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rafael CartayaFamily Medicine, Nova Medical Services, Miami, USA.
Syed A A RizviBiomedical Sciences, Larkin University, Miami, USA.
Viviane ManaraPulmonary and Critical Care, Ferrer Pulmonary Institute, Hallandale Beach, USA.
Mari L TeschResearch and Development, Dr. Ferrer Biopharma, Hallandale, USA.
Rahaghi FranckPulmonary and Critical Care Medicine, Cleveland Clinic Florida, Weston, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A patient with multiple comorbidities and an eight-year history of tracheostomy was being treated for tracheitis. At this point, she became incapable of using regular speaking valves, and multiple attempts to reintroduce the speaking valve failed. A Ferrer adjustable speaking valve (FASV) was designed with gradations of outflow closure, allowing air to go through the vocal cords for phonation. The FASV was offered to her through the compassionate use program at the FDA. At 20% initial closure, the patient was able to tolerate the valve and was advanced to 50% closure, at which point she could phonate partially. The use of the valve was terminated at the time of her transfer, 23 days after the initiation of use. This suggests the safety and possible efficacy of using an adjustable speaking valve earlier than regular valves, allowing patients to communicate earlier and further exercise their diaphragms.

Indexed as

home health nursingrespiratory supportspeaking valvetracheostomyvoice related quality of life

Identifiers

PMID38868548
PMCPMC11168738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.